Table A2:
Applicability of Included Studies in the Economic Literature Review
| Objective: To assess the cost-effectiveness of SCIG versus IVIG treatment | |||||
|---|---|---|---|---|---|
| Author, year | Is the study population similar to the question? | Are the interventions similar to the question? | Is the health care system in which the study was conducted sufficiently similar to the current Ontario context? | Was the perspective clearly stated and what was it? | Are estimates of relative treatment effect from the best available source? |
| Gerth et al,201411 | Yes | Yes | Yes (Canada) | Yes; Public payer | Not applicable |
| Martin et al,201334 | Yes | Yes | Yes (Canada) | Yes; Public payer | Not applicable |
| CADTH, 200835 (First analysis)a | Yes | Yes | Yes (Canada) | Yes; Public payer | Not applicable |
| CADTH, 2008 (Second analysis)b | Yes | Yes | Yes (Canada) | Yes; Public payer | Partly |
| Beauteet al200936 (First analysis)a | Yes | Yes | Yes (France) | Yes; Public payer | Not applicable |
| Beauteet al 200936 (Second analysis)c | Yes | Yes | Yes (France) | Yes; Public payer | Not applicable |
| Author, year | Are all future costs and outcomes discounted? (If yes, at what rate?) | Is the value of health effects expressed in terms of quality-adjusted life-years? | Are costs from other sectors fully and appropriately measured and valued? | Overall judgement (directly applicable/partially applicable/not applicable) | |
|---|---|---|---|---|---|
| Gerth et al, 201411 | Not applicable | Not applicable | Partly | Partially Applicable | |
| Martin et al, 201334 | No | Not applicable | Partly | Partially Applicable | |
| CADTH, 200835 (First analysis)a | Not applicable | Not applicable | Partly | Partially Applicable | |
| CADTH, 2008 (Second analysis)b | Not applicable | Yes | Partly | Partially Applicable | |
| Beauteet al 200936 (First analysis)a | Not applicable | Not applicable | Partly | Not Applicable | |
| Beauteet al 200936 (Second analysis)c | Not applicable | Not applicable | No | Not Applicable | |
Abbreviations: IVIG, hospital-based intravenous immunoglobulin; SCIG, home-based subcutaneous immunoglobulin.
a
In the first analysis, authors assumed that SCIG and IVIG would yield identical clinical outcomes, and then conducted the cost minimization analysis.
b
In the second analysis, authors assumed that SCIG and IVIG would yield different clinical outcomes, and then conducted the cost utility analysis.
c
Authors included eight patients with SCIG therapy and 26 patients with IVIG therapy. The crude results were reported.